- Companies
- Abeona Therapeutics
Abeona Therapeutics Valuation Multiples
Abeona Therapeutics is valued at $238M as of November 2026, a 2.4x revenue multiple. In the last 12 months, Abeona Therapeutics revenue was $46M.
Abeona Therapeutics Overview
About Abeona Therapeutics
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Founded
1974
HQ
Employees
226
Website
Financials (LTM)
EV
$112M
Valuation Multiples
Start free trialAbeona Therapeutics Financials
Abeona Therapeutics reported last 12-month revenue of $46M.
In the same LTM period, Abeona Therapeutics generated $33M in gross profit and had net loss of ($38M).
Revenue (LTM)
Abeona Therapeutics P&L
In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of ($75M).
Abeona Therapeutics is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of (1283%), and net margin of 1223%.
Financial data powered by Morningstar, Inc.
Abeona Therapeutics Stock Performance
Abeona Therapeutics has current market cap of $238M, and enterprise value of $112M.
Market Cap Evolution
Abeona Therapeutics' stock price is $4.17.
Abeona Therapeutics share price decreased by 4.1% in the last 30 days, and by 17.8% in the last year.
Abeona Therapeutics has an EPS (earnings per share) of $1.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $112M | $238M | 0.0% | -4.1% | -28.8% | -17.8% | $1.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbeona Therapeutics Valuation Multiples
Abeona Therapeutics trades at 2.4x EV/Revenue multiple, and (1.5x) EV/EBITDA.
EV / Revenue (LTM)
Abeona Therapeutics Financial Valuation Multiples
As of November 9, 2026, Abeona Therapeutics has market cap of $238M and EV of $112M.
Abeona Therapeutics has a P/E ratio of (6.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abeona Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Abeona Therapeutics Margins & Growth Rates
Abeona Therapeutics grew revenue by 804% but net profit decreased by 179% in the last fiscal year.
In the most recent fiscal year, Abeona Therapeutics reported gross margin of 41%, EBITDA margin of (1283%), and net margin of 1223%.
Abeona Therapeutics Margins
Abeona Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Operational KPIs
Abeona Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Competitors
Abeona Therapeutics competitors include Immuneering, ProKidney, Lexeo Therapeutics, Boan Biotech, Dong-A ST, Abclon, Jacobson Pharma, Evommune, Reig Jofré and Amarin Corp.
Most Abeona Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($59M) | - | - | (1.6x) | - | |||
| $893K | ($158M) | 1306.3x | 2008.3x | (7.4x) | (6.4x) | |||
| - | ($104M) | - | - | (0.3x) | (0.3x) | |||
| $118M | $19M | 1.7x | 1.7x | 10.2x | 29.8x | |||
| $597M | $6M | 0.8x | 0.8x | 81.5x | 9.0x | |||
| $3M | ($12M) | 63.0x | - | (17.7x) | - | |||
| $200M | $69M | 1.5x | - | 4.5x | - | |||
| $13M | ($71M) | 3.7x | 26.3x | (0.7x) | (0.4x) | |||
This data is available for Pro users. Sign up to see all Abeona Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abeona Therapeutics
| When was Abeona Therapeutics founded? | Abeona Therapeutics was founded in 1974. |
| Where is Abeona Therapeutics headquartered? | Abeona Therapeutics is headquartered in United States. |
| How many employees does Abeona Therapeutics have? | As of today, Abeona Therapeutics has over 226 employees. |
| Who is the CEO of Abeona Therapeutics? | Abeona Therapeutics' CEO is Vishwas Seshadri. |
| Is Abeona Therapeutics publicly listed? | Yes, Abeona Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Abeona Therapeutics? | Abeona Therapeutics trades under ABEO ticker. |
| When did Abeona Therapeutics go public? | Abeona Therapeutics went public in 1980. |
| Who are competitors of Abeona Therapeutics? | Abeona Therapeutics main competitors include Immuneering, ProKidney, Lexeo Therapeutics, Boan Biotech, Dong-A ST, Abclon, Jacobson Pharma, Evommune, Reig Jofré, Amarin Corp. |
| What is the current market cap of Abeona Therapeutics? | Abeona Therapeutics' current market cap is $238M. |
| What is the current revenue of Abeona Therapeutics? | Abeona Therapeutics' last 12 months revenue is $46M. |
| What is the current revenue growth of Abeona Therapeutics? | Abeona Therapeutics revenue growth (NTM/LTM) is 132%. |
| What is the current EV/Revenue multiple of Abeona Therapeutics? | Current revenue multiple of Abeona Therapeutics is 2.4x. |
| Is Abeona Therapeutics profitable? | No, Abeona Therapeutics is not profitable. |
| What is the current net income of Abeona Therapeutics? | Abeona Therapeutics' last 12 months net income is ($38M). |
| How many companies Abeona Therapeutics has acquired to date? | Abeona Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Abeona Therapeutics has invested to date? | Abeona Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Abeona Therapeutics
Lists including Abeona Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




